Biologics in pediatric chronic rhinosinusitis with nasal polyps: A systematic review of efficacy and safety.

What was studied

This review looked at biologic drugs for nasal polyps in children. The illness is long-term sinus swelling with growths in the nose. The team searched PubMed, Scopus and the Cochrane Library up to March 2026. They looked for studies of children with type 2 airway disease. Studies on cystic fibrosis or fungal sinus disease were kept apart. Of 404 records found, few studies could be used. The main part used case series and one study that looked back at records.

What they found

The proof was mostly weak, mixed, and based on few patients. Dupilumab, omalizumab and mepolizumab showed signs that they might help. These signs were seen in some children with type 2 swelling. Nose and sinus results were not reported in the same way. No major safety problems from the drugs were reported. For dupilumab, there is little safety data in these children. Its known side effects include skin reactions where it is given. Others are skin rashes, joint pain and red, sore eyes. It can also raise the level of certain white blood cells. The authors say these need close watching.

What it means for patients

The authors say biologics may help some children need fewer steroids. This is for type 2 polyps that do not get better with other care. But they say their view should be taken with care. The results mainly raise ideas for new studies to test.

Why it is not certain yet

Most of the studies were case series with no comparison group. Groups were small and the study methods varied. Side effects were not always reported clearly. Follow-up was short and differed between studies. Some of the data came from related groups, not straight from these children. The authors call for new studies in children with longer follow-up. A review can only be as good as the studies in it.

Source

Biologics in pediatric chronic rhinosinusitis with nasal polyps: A systematic review of efficacy and safety.

We restate facts from the source record in our own words. The original wording belongs to its publisher.